Pathogenic  ||| S:0 E:11 ||| NNP
and  ||| S:11 E:15 ||| CC
clinical  ||| S:15 E:24 ||| JJ
presentation  ||| S:24 E:37 ||| NN
of  ||| S:37 E:40 ||| IN
bullous  ||| S:40 E:48 ||| JJ
rash  ||| S:48 E:53 ||| NN
in  ||| S:53 E:56 ||| IN
hand ||| S:56 E:60 ||| NN
,  ||| S:60 E:62 ||| ,
foot  ||| S:62 E:67 ||| NN
and  ||| S:67 E:71 ||| CC
mouth  ||| S:71 E:77 ||| NN
disease  ||| S:77 E:85 ||| NN
To  ||| S:85 E:88 ||| TO
investigate  ||| S:88 E:100 ||| VB
the  ||| S:100 E:104 ||| DT
pathogenic  ||| S:104 E:115 ||| NN
and  ||| S:115 E:119 ||| CC
clinical  ||| S:119 E:128 ||| JJ
presentation  ||| S:128 E:141 ||| NN
and  ||| S:141 E:145 ||| CC
laboratory  ||| S:145 E:156 ||| NN
tests  ||| S:156 E:162 ||| NNS
of  ||| S:162 E:165 ||| IN
bullous  ||| S:165 E:173 ||| JJ
rash  ||| S:173 E:178 ||| NN
in  ||| S:178 E:181 ||| IN
hand ||| S:181 E:185 ||| NN
,  ||| S:185 E:187 ||| ,
foot  ||| S:187 E:192 ||| NN
and  ||| S:192 E:196 ||| CC
mouth  ||| S:196 E:202 ||| NN
disease  ||| S:202 E:210 ||| NN
( ||| S:210 E:211 ||| -LRB-
HFMD ||| S:211 E:215 ||| NNP
)  ||| S:215 E:217 ||| -RRB-
in  ||| S:217 E:220 ||| IN
Xi ||| S:220 E:222 ||| NNP
' ||| S:222 E:223 ||| POS
an  ||| S:223 E:226 ||| NN
from  ||| S:226 E:231 ||| IN
January  ||| S:231 E:239 ||| NNP
2013  ||| S:239 E:244 ||| CD
to  ||| S:244 E:247 ||| TO
December  ||| S:247 E:256 ||| NNP
2014  ||| S:256 E:261 ||| CD
by  ||| S:261 E:264 ||| IN
retrospective  ||| S:264 E:278 ||| JJ
analysis ||| S:278 E:286 ||| NN
.  ||| S:286 E:288 ||| .
A  ||| S:288 E:290 ||| DT
total  ||| S:290 E:296 ||| NN
of  ||| S:296 E:299 ||| IN
224  ||| S:299 E:303 ||| CD
specimens  ||| S:303 E:313 ||| NNS
were  ||| S:313 E:318 ||| VBD
collected  ||| S:318 E:328 ||| VBN
from  ||| S:328 E:333 ||| IN
clinically  ||| S:333 E:344 ||| NN
diagnosed  ||| S:344 E:354 ||| VBD
HFMD  ||| S:354 E:359 ||| NNP
cases  ||| S:359 E:365 ||| NNS
who  ||| S:365 E:369 ||| WP
were  ||| S:369 E:374 ||| VBD
characterized  ||| S:374 E:388 ||| VBN
by  ||| S:388 E:391 ||| IN
widespread  ||| S:391 E:402 ||| JJ
mucocutaneous  ||| S:402 E:416 ||| JJ
bullous  ||| S:416 E:424 ||| JJ
reactions  ||| S:424 E:434 ||| NNS
in  ||| S:434 E:437 ||| IN
Xi ||| S:437 E:439 ||| NNP
' ||| S:439 E:440 ||| ''
an  ||| S:440 E:443 ||| DT
Children ||| S:443 E:451 ||| NNP
's  ||| S:451 E:454 ||| POS
Hospital  ||| S:454 E:463 ||| NN
from  ||| S:463 E:468 ||| IN
January  ||| S:468 E:476 ||| NNP
2013  ||| S:476 E:481 ||| CD
to  ||| S:481 E:484 ||| TO
December  ||| S:484 E:493 ||| NNP
2014 ||| S:493 E:497 ||| CD
,  ||| S:497 E:499 ||| ,
the  ||| S:499 E:503 ||| DT
identification  ||| S:503 E:518 ||| NN
and  ||| S:518 E:522 ||| CC
subtyping  ||| S:522 E:532 ||| NN
of  ||| S:532 E:535 ||| IN
the  ||| S:535 E:539 ||| DT
isolates  ||| S:539 E:548 ||| NN
were  ||| S:548 E:553 ||| VBD
conducted  ||| S:553 E:563 ||| VBN
with  ||| S:563 E:568 ||| IN
real-time  ||| S:568 E:578 ||| JJ
fluorescent  ||| S:578 E:590 ||| JJ
quantitative  ||| S:590 E:603 ||| JJ
RT-PCR ||| S:603 E:609 ||| NN
.  ||| S:609 E:611 ||| .
A  ||| S:611 E:613 ||| DT
retrospective  ||| S:613 E:627 ||| JJ
analysis  ||| S:627 E:636 ||| NN
was  ||| S:636 E:640 ||| VBD
performed  ||| S:640 E:650 ||| VBN
to  ||| S:650 E:653 ||| TO
analyze  ||| S:653 E:661 ||| VB
the  ||| S:661 E:665 ||| DT
clinical  ||| S:665 E:674 ||| JJ
presentation ||| S:674 E:686 ||| NN
,  ||| S:686 E:688 ||| ,
laboratory  ||| S:688 E:699 ||| NN
tests  ||| S:699 E:705 ||| NNS
and  ||| S:705 E:709 ||| CC
late  ||| S:709 E:714 ||| JJ
follow-up  ||| S:714 E:724 ||| JJ
problems  ||| S:724 E:733 ||| NNS
of  ||| S:733 E:736 ||| IN
the  ||| S:736 E:740 ||| DT
HFMD ||| S:740 E:744 ||| NNP
.  ||| S:744 E:746 ||| .
In  ||| S:746 E:749 ||| IN
the  ||| S:749 E:753 ||| DT
clinically  ||| S:753 E:764 ||| NN
diagnosed  ||| S:764 E:774 ||| VBD
HFMD  ||| S:774 E:779 ||| NNP
cases  ||| S:779 E:785 ||| NNS
who  ||| S:785 E:789 ||| WP
were  ||| S:789 E:794 ||| VBD
characterized  ||| S:794 E:808 ||| VBN
by  ||| S:808 E:811 ||| IN
widespread  ||| S:811 E:822 ||| JJ
mucocutaneous  ||| S:822 E:836 ||| JJ
bullous  ||| S:836 E:844 ||| JJ
reactions ||| S:844 E:853 ||| NNS
,  ||| S:853 E:855 ||| ,
207  ||| S:855 E:859 ||| CD
were  ||| S:859 E:864 ||| VBD
caused  ||| S:864 E:871 ||| VBN
by  ||| S:871 E:874 ||| IN
coxsackievirus  ||| S:874 E:889 ||| CD
A6  ||| S:889 E:892 ||| CD
( ||| S:892 E:893 ||| -LRB-
CA6 ||| S:893 E:896 ||| NNP
) ||| S:896 E:897 ||| -RRB-
,  ||| S:897 E:899 ||| ,
accounting  ||| S:899 E:910 ||| NN
for  ||| S:910 E:914 ||| IN
92.  ||| S:914 E:918 ||| CD
4 ||| S:918 E:919 ||| CD
%  ||| S:919 E:921 ||| NN
of  ||| S:921 E:924 ||| IN
all  ||| S:924 E:928 ||| DT
cases  ||| S:928 E:934 ||| NNS
with  ||| S:934 E:939 ||| IN
bullous ||| S:939 E:946 ||| NN
,  ||| S:946 E:948 ||| ,
4  ||| S:948 E:950 ||| CD
were  ||| S:950 E:955 ||| VBD
caused  ||| S:955 E:962 ||| VBN
by  ||| S:962 E:965 ||| IN
enterovirus  ||| S:965 E:977 ||| CD
71  ||| S:977 E:980 ||| CD
( ||| S:980 E:981 ||| -LRB-
EV71 ||| S:981 E:985 ||| NNP
) ||| S:985 E:986 ||| -RRB-
,  ||| S:986 E:988 ||| ,
accounting  ||| S:988 E:999 ||| NN
for  ||| S:999 E:1003 ||| IN
1.8 ||| S:1003 E:1006 ||| CD
% ||| S:1006 E:1007 ||| NN
,  ||| S:1007 E:1009 ||| ,
10  ||| S:1009 E:1012 ||| CD
were  ||| S:1012 E:1017 ||| VBD
caused  ||| S:1017 E:1024 ||| VBN
by  ||| S:1024 E:1027 ||| IN
coxsackievirus  ||| S:1027 E:1042 ||| CD
A16  ||| S:1042 E:1046 ||| CD
( ||| S:1046 E:1047 ||| -LRB-
CA16 ||| S:1047 E:1051 ||| NNP
) ||| S:1051 E:1052 ||| -RRB-
,  ||| S:1052 E:1054 ||| ,
accounting  ||| S:1054 E:1065 ||| NN
for  ||| S:1065 E:1069 ||| IN
4.  ||| S:1069 E:1072 ||| CD
5 ||| S:1072 E:1073 ||| CD
% ||| S:1073 E:1074 ||| NN
;  ||| S:1074 E:1076 ||| :
4  ||| S:1076 E:1078 ||| CD
cases  ||| S:1078 E:1084 ||| NNS
were  ||| S:1084 E:1089 ||| VBD
negative  ||| S:1089 E:1098 ||| JJ
for  ||| S:1098 E:1102 ||| IN
these  ||| S:1102 E:1108 ||| DT
viruses ||| S:1108 E:1115 ||| NN
.  ||| S:1115 E:1117 ||| .
In  ||| S:1117 E:1120 ||| IN
the  ||| S:1120 E:1124 ||| DT
cases  ||| S:1124 E:1130 ||| NNS
positive  ||| S:1130 E:1139 ||| JJ
for  ||| S:1139 E:1143 ||| IN
intestinal  ||| S:1143 E:1154 ||| JJ
virus-nucleic  ||| S:1154 E:1168 ||| JJ
acid ||| S:1168 E:1172 ||| NN
,  ||| S:1172 E:1174 ||| ,
130  ||| S:1174 E:1178 ||| CD
were  ||| S:1178 E:1183 ||| VBD
male ||| S:1183 E:1187 ||| JJ
,  ||| S:1187 E:1189 ||| ,
90  ||| S:1189 E:1192 ||| CD
were  ||| S:1192 E:1197 ||| VBD
female ||| S:1197 E:1203 ||| JJ
;  ||| S:1203 E:1205 ||| :
male  ||| S:1205 E:1210 ||| JJ
to  ||| S:1210 E:1213 ||| TO
female  ||| S:1213 E:1220 ||| JJ
ratio  ||| S:1220 E:1226 ||| NN
was  ||| S:1226 E:1230 ||| VBD
1.  ||| S:1230 E:1233 ||| CD
44 ||| S:1233 E:1235 ||| CD
:  ||| S:1235 E:1237 ||| :
1 ||| S:1237 E:1238 ||| CD
,  ||| S:1238 E:1240 ||| ,
203  ||| S:1240 E:1244 ||| CD
were  ||| S:1244 E:1249 ||| VBD
< ||| S:1249 E:1250 ||| SYM
5  ||| S:1250 E:1252 ||| CD
years  ||| S:1252 E:1258 ||| NNS
old ||| S:1258 E:1261 ||| JJ
,  ||| S:1261 E:1263 ||| ,
accounting  ||| S:1263 E:1274 ||| NN
for  ||| S:1274 E:1278 ||| IN
92.  ||| S:1278 E:1282 ||| CD
3 ||| S:1282 E:1283 ||| CD
% ||| S:1283 E:1284 ||| NN
.  ||| S:1284 E:1286 ||| .
Leukocytosis  ||| S:1286 E:1299 ||| NNP
was  ||| S:1299 E:1303 ||| VBD
found  ||| S:1303 E:1309 ||| VBN
in  ||| S:1309 E:1312 ||| IN
75  ||| S:1312 E:1315 ||| CD
cases  ||| S:1315 E:1321 ||| NNS
( ||| S:1321 E:1322 ||| -LRB-
34.  ||| S:1322 E:1326 ||| CD
1 ||| S:1326 E:1327 ||| CD
% ||| S:1327 E:1328 ||| NN
) ||| S:1328 E:1329 ||| -RRB-
;  ||| S:1329 E:1331 ||| :
high-sensitivity  ||| S:1331 E:1348 ||| JJ
C-reactive  ||| S:1348 E:1359 ||| JJ
protein  ||| S:1359 E:1367 ||| NN
( ||| S:1367 E:1368 ||| -LRB-
hsCRP ||| S:1368 E:1373 ||| NNP
)  ||| S:1373 E:1375 ||| -RRB-
increased  ||| S:1375 E:1385 ||| VBD
in  ||| S:1385 E:1388 ||| IN
200  ||| S:1388 E:1392 ||| CD
cases  ||| S:1392 E:1398 ||| NNS
( ||| S:1398 E:1399 ||| -LRB-
90.  ||| S:1399 E:1403 ||| CD
9 ||| S:1403 E:1404 ||| CD
% ||| S:1404 E:1405 ||| NN
) ||| S:1405 E:1406 ||| -RRB-
;  ||| S:1406 E:1408 ||| :
elevated  ||| S:1408 E:1417 ||| FW
myocardial  ||| S:1417 E:1428 ||| FW
enzyme  ||| S:1428 E:1435 ||| FW
CK-MB  ||| S:1435 E:1441 ||| NNP
was  ||| S:1441 E:1445 ||| VBD
found  ||| S:1445 E:1451 ||| VBN
in  ||| S:1451 E:1454 ||| IN
35  ||| S:1454 E:1457 ||| CD
cases  ||| S:1457 E:1463 ||| NNS
( ||| S:1463 E:1464 ||| -LRB-
15.  ||| S:1464 E:1468 ||| CD
9 ||| S:1468 E:1469 ||| CD
% ||| S:1469 E:1470 ||| NN
) ||| S:1470 E:1471 ||| -RRB-
,  ||| S:1471 E:1473 ||| ,
alanine  ||| S:1473 E:1481 ||| NNS
aminotransferase  ||| S:1481 E:1498 ||| VBP
increased  ||| S:1498 E:1508 ||| VBN
in  ||| S:1508 E:1511 ||| IN
15  ||| S:1511 E:1514 ||| CD
cases  ||| S:1514 E:1520 ||| NNS
( ||| S:1520 E:1521 ||| -LRB-
6.  ||| S:1521 E:1524 ||| CD
8 ||| S:1524 E:1525 ||| CD
% ||| S:1525 E:1526 ||| NN
) ||| S:1526 E:1527 ||| -RRB-
;  ||| S:1527 E:1529 ||| :
187  ||| S:1529 E:1533 ||| CD
cases  ||| S:1533 E:1539 ||| NNS
had  ||| S:1539 E:1543 ||| VBD
fever  ||| S:1543 E:1549 ||| NN
( ||| S:1549 E:1550 ||| -LRB-
85.  ||| S:1550 E:1554 ||| CD
0 ||| S:1554 E:1555 ||| CD
% ||| S:1555 E:1556 ||| NN
) ||| S:1556 E:1557 ||| -RRB-
.  ||| S:1557 E:1559 ||| .
None  ||| S:1559 E:1564 ||| NN
of  ||| S:1564 E:1567 ||| IN
the  ||| S:1567 E:1571 ||| DT
cases  ||| S:1571 E:1577 ||| NNS
had  ||| S:1577 E:1581 ||| VBD
serious  ||| S:1581 E:1589 ||| JJ
complications  ||| S:1589 E:1603 ||| NNS
such  ||| S:1603 E:1608 ||| JJ
as  ||| S:1608 E:1611 ||| IN
encephalitis  ||| S:1611 E:1624 ||| NN
or  ||| S:1624 E:1627 ||| CC
myocarditis ||| S:1627 E:1638 ||| NN
.  ||| S:1638 E:1640 ||| .
In  ||| S:1640 E:1643 ||| IN
the  ||| S:1643 E:1647 ||| DT
course  ||| S:1647 E:1654 ||| NN
of  ||| S:1654 E:1657 ||| IN
the  ||| S:1657 E:1661 ||| DT
critical  ||| S:1661 E:1670 ||| JJ
phase  ||| S:1670 E:1676 ||| NN
bullous  ||| S:1676 E:1684 ||| NN
rash  ||| S:1684 E:1689 ||| NN
or  ||| S:1689 E:1692 ||| CC
large  ||| S:1692 E:1698 ||| JJ
vesicle-like  ||| S:1698 E:1711 ||| JJ
changes ||| S:1711 E:1718 ||| NNS
,  ||| S:1718 E:1720 ||| ,
obvious  ||| S:1720 E:1728 ||| JJ
itching ||| S:1728 E:1735 ||| NN
,  ||| S:1735 E:1737 ||| ,
and  ||| S:1737 E:1741 ||| CC
facial  ||| S:1741 E:1748 ||| JJ
rash  ||| S:1748 E:1753 ||| NN
appeared ||| S:1753 E:1761 ||| VBD
.  ||| S:1761 E:1763 ||| .
After  ||| S:1763 E:1769 ||| IN
the  ||| S:1769 E:1773 ||| DT
fluid  ||| S:1773 E:1779 ||| NN
in  ||| S:1779 E:1782 ||| IN
the  ||| S:1782 E:1786 ||| DT
bullae  ||| S:1786 E:1793 ||| NN
was  ||| S:1793 E:1797 ||| VBD
absorbed  ||| S:1797 E:1806 ||| VBN
or  ||| S:1806 E:1809 ||| CC
the  ||| S:1809 E:1813 ||| DT
bullae  ||| S:1813 E:1820 ||| JJ
ruptured  ||| S:1820 E:1829 ||| NN
or  ||| S:1829 E:1832 ||| CC
became  ||| S:1832 E:1839 ||| VBD
ulcerated ||| S:1839 E:1848 ||| CD
,  ||| S:1848 E:1850 ||| ,
scar  ||| S:1850 E:1855 ||| JJ
formation  ||| S:1855 E:1865 ||| NN
and  ||| S:1865 E:1869 ||| CC
large  ||| S:1869 E:1875 ||| JJ
areas  ||| S:1875 E:1881 ||| NNS
of  ||| S:1881 E:1884 ||| IN
exfoliation  ||| S:1884 E:1896 ||| NN
occurred ||| S:1896 E:1904 ||| VBD
,  ||| S:1904 E:1906 ||| ,
with  ||| S:1906 E:1911 ||| IN
no  ||| S:1911 E:1914 ||| DT
effusion  ||| S:1914 E:1923 ||| NN
on  ||| S:1923 E:1926 ||| IN
the  ||| S:1926 E:1930 ||| DT
newly  ||| S:1930 E:1936 ||| RB
formed  ||| S:1936 E:1943 ||| VBN
epithelium  ||| S:1943 E:1954 ||| VBN
in  ||| S:1954 E:1957 ||| IN
the  ||| S:1957 E:1961 ||| DT
base ||| S:1961 E:1965 ||| NN
,  ||| S:1965 E:1967 ||| ,
without  ||| S:1967 E:1975 ||| IN
significant  ||| S:1975 E:1987 ||| JJ
pigmentation  ||| S:1987 E:2000 ||| NN
on  ||| S:2000 E:2003 ||| IN
later  ||| S:2003 E:2009 ||| RB
follow-up ||| S:2009 E:2018 ||| JJ
.  ||| S:2018 E:2020 ||| .
In  ||| S:2020 E:2023 ||| IN
the  ||| S:2023 E:2027 ||| DT
late  ||| S:2027 E:2032 ||| RB
follow  ||| S:2032 E:2039 ||| VB
up  ||| S:2039 E:2042 ||| RP
process ||| S:2042 E:2049 ||| NN
,  ||| S:2049 E:2051 ||| ,
52  ||| S:2051 E:2054 ||| CD
cases  ||| S:2054 E:2060 ||| NNS
in  ||| S:2060 E:2063 ||| IN
CA6-positive  ||| S:2063 E:2076 ||| CD
patients  ||| S:2076 E:2085 ||| NNS
( ||| S:2085 E:2086 ||| -LRB-
25.  ||| S:2086 E:2090 ||| CD
1 ||| S:2090 E:2091 ||| CD
% ||| S:2091 E:2092 ||| NN
)  ||| S:2092 E:2094 ||| -RRB-
developed  ||| S:2094 E:2104 ||| VBD
onychomadesis  ||| S:2104 E:2118 ||| VBN
within  ||| S:2118 E:2125 ||| IN
2-4  ||| S:2125 E:2129 ||| CD
weeks  ||| S:2129 E:2135 ||| NNS
after  ||| S:2135 E:2141 ||| IN
onset ||| S:2141 E:2146 ||| NN
,  ||| S:2146 E:2148 ||| ,
1  ||| S:2148 E:2150 ||| CD
to  ||| S:2150 E:2153 ||| TO
8  ||| S:2153 E:2155 ||| CD
nails ||| S:2155 E:2160 ||| NN
,  ||| S:2160 E:2162 ||| ,
an  ||| S:2162 E:2165 ||| DT
average  ||| S:2165 E:2173 ||| NN
of  ||| S:2173 E:2176 ||| IN
4.  ||| S:2176 E:2179 ||| CD
3  ||| S:2179 E:2181 ||| CD
fell  ||| S:2181 E:2186 ||| VBD
off ||| S:2186 E:2189 ||| RP
,  ||| S:2189 E:2191 ||| ,
new  ||| S:2191 E:2195 ||| JJ
nails  ||| S:2195 E:2201 ||| NN
grew ||| S:2201 E:2205 ||| VBD
,  ||| S:2205 E:2207 ||| ,
the  ||| S:2207 E:2211 ||| DT
nail  ||| S:2211 E:2216 ||| JJ
bed  ||| S:2216 E:2220 ||| NN
showed  ||| S:2220 E:2227 ||| VBD
no  ||| S:2227 E:2230 ||| DT
structural  ||| S:2230 E:2241 ||| JJ
abnormalities  ||| S:2241 E:2255 ||| NN
and  ||| S:2255 E:2259 ||| CC
hyperplasia  ||| S:2259 E:2271 ||| NN
after  ||| S:2271 E:2277 ||| IN
falling  ||| S:2277 E:2285 ||| VBG
off ||| S:2285 E:2288 ||| RP
,  ||| S:2288 E:2290 ||| ,
the  ||| S:2290 E:2294 ||| DT
surface  ||| S:2294 E:2302 ||| NN
was  ||| S:2302 E:2306 ||| VBD
smooth ||| S:2306 E:2312 ||| JJ
,  ||| S:2312 E:2314 ||| ,
had  ||| S:2314 E:2318 ||| VBD
no  ||| S:2318 E:2321 ||| DT
hypertrophy ||| S:2321 E:2332 ||| NN
,  ||| S:2332 E:2334 ||| ,
left  ||| S:2334 E:2339 ||| VBD
no  ||| S:2339 E:2342 ||| DT
sequelae ||| S:2342 E:2350 ||| NN
.  ||| S:2350 E:2352 ||| .
The  ||| S:2352 E:2356 ||| DT
pathogen  ||| S:2356 E:2365 ||| NN
in  ||| S:2365 E:2368 ||| IN
HFMD  ||| S:2368 E:2373 ||| NNP
characterized  ||| S:2373 E:2387 ||| VBD
by  ||| S:2387 E:2390 ||| IN
widespread  ||| S:2390 E:2401 ||| JJ
bullous  ||| S:2401 E:2409 ||| JJ
reactions  ||| S:2409 E:2419 ||| NNS
was  ||| S:2419 E:2423 ||| VBD
mainly  ||| S:2423 E:2430 ||| RB
the  ||| S:2430 E:2434 ||| DT
CA6 ||| S:2434 E:2437 ||| NNP
,  ||| S:2437 E:2439 ||| ,
this  ||| S:2439 E:2444 ||| DT
kind  ||| S:2444 E:2449 ||| NN
of  ||| S:2449 E:2452 ||| IN
HFMD  ||| S:2452 E:2457 ||| NNP
was  ||| S:2457 E:2461 ||| VBD
mainly  ||| S:2461 E:2468 ||| RB
mild  ||| S:2468 E:2473 ||| JJ
type ||| S:2473 E:2477 ||| NN
,  ||| S:2477 E:2479 ||| ,
with  ||| S:2479 E:2484 ||| IN
significant  ||| S:2484 E:2496 ||| JJ
itching ||| S:2496 E:2503 ||| NN
,  ||| S:2503 E:2505 ||| ,
later  ||| S:2505 E:2511 ||| RB
the  ||| S:2511 E:2515 ||| DT
bullae  ||| S:2515 E:2522 ||| NN
may  ||| S:2522 E:2526 ||| MD
have  ||| S:2526 E:2531 ||| VB
scar  ||| S:2531 E:2536 ||| JJ
formation  ||| S:2536 E:2546 ||| NN
and  ||| S:2546 E:2550 ||| CC
skin  ||| S:2550 E:2555 ||| NN
exfoliation ||| S:2555 E:2566 ||| NN
,  ||| S:2566 E:2568 ||| ,
in  ||| S:2568 E:2571 ||| IN
some  ||| S:2571 E:2576 ||| DT
cases  ||| S:2576 E:2582 ||| NNS
onychomadesis  ||| S:2582 E:2596 ||| NN
may  ||| S:2596 E:2600 ||| MD
occur ||| S:2600 E:2605 ||| VB
.  ||| S:2605 E:2607 ||| .
